表紙
市場調查報告書

霉漿菌屬檢驗的全球市場:各產品、技術、應用、地理的成長率,趨勢及預測(2018年∼2023年)

Mycoplasma Testing Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 660998
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
霉漿菌屬檢驗的全球市場:各產品、技術、應用、地理的成長率,趨勢及預測(2018年∼2023年) Mycoplasma Testing Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年06月01日內容資訊: 英文 114 Pages
簡介

全球霉漿菌屬檢驗市場,預計從2018年到2023年的預測期間內,10.4%的年複合成長率成長。北美,因為地區內實施的生命科學研究活動數多,預計在預測期間內主導市場。

本報告提供全球霉漿菌屬檢驗市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 市場定義

第2章 調查方法

第3章 摘要整理

第4章 主要影響要素

第5章 市場概要

  • 目前市場方案
  • 波特的五力分析
    • 供應商談判力
    • 消費者談判力
    • 新加入廠商的威脅
    • 替代產品及服務的威脅
    • 產業內的競爭

第6章 成長要素,阻礙因素,機會,課題分析(DROC)

  • 成長要素
    • 研究活動中政府的積極推動與資金籌措的增加
    • 研究開發活動的投資高漲
    • 對迅速正確合理價格的檢驗的需求增加
    • 細胞培養污染的增加
  • 阻礙因素
    • 嚴格的政府法規
    • 新加入廠商高的整合
  • 市場機會
  • 主要課題

第7章 市場區隔

  • 各產品
    • 器具
    • 套件及試劑
  • 各技術
    • PCR
    • ELISA
    • 直接化驗
    • 間接化驗
    • 微生物培養技術
    • 其他
  • 各應用領域
    • 細胞株的實驗
    • 病毒檢驗
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第8章 競爭情形

  • M&A分析
  • 協定,合作,夥伴關係
  • 新產品的銷售

第9章 主要企業

  • Abbott
  • Agilent Technologies
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche Ltd
  • Lonza Group
  • Merck KGaA
  • PromoCell GmbH
  • Sartorius AG
  • Thermo Fisher Scientific, Inc. 等

第10章 市場未來展望

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 51949

Market Overview

The global mycoplasma testing market is estimated to register a healthy CAGR over the forecast period. The factors such as high spending into R&D activities by biopharmaceutical companies increased governmental initiatives, and funding in research activities, technological advancements, increasing demand for fast, accurate and affordable testing, and increasing cell culture contamination are further driving the market for mycoplasma testing. However, there are certain stringent government regulations across several developed and emerging countries and high degree of consolidation for new entrants which are among the major hindrances to the mycoplasma testing market growth.

Scope of the Report

The term "mycoplasma" refers to a class of bacteria that is commonly present in cell culture. More correctly known as mollicutes, these bacteria lack a cell wall, making them resistant to commonly used antibiotics such as penicillin. Mycoplasma is easily spread through droplets during cell culture and can survive in dried form for months. Mycoplasma contamination is difficult to see with a microscope and requires specific testing to be detected. Contamination can have a profound impact on experimental work. Depending on the species present, mycoplasma organisms can affect cell growth, metabolism, tumourigenicity, and response to chemotherapy.

Key Market Trends

Polymerase Chain Reaction (PCR) holds significant market share

Polymerase Chain Reaction (PCR) is a technique which is used to amplify target DNA and to generate thousands to millions of copies of a particular DNA segment. PCR techniques are used in clinical and research laboratories for a broad variety of applications which includes clinical diagnosis, criminal forensics, and biomedical research. The major factors attributing the growth of the polymerase chain reaction segment includes the increasing application in clinical diagnostics, rising demand for personalized and precision medicine, and technological advancements and application in drug development. For instance, in July 2018, ATCC, the premier global biological materials resource and standards organization and the leading supplier of authenticated cells and advanced cell models, launched its new PCR-based service to detect mycoplasma contamination in cell cultures. ATCC has long recognized the growing challenges among the scientific community for adventitious agent contamination included in cell-based research hence the company introduced this product line to support the authentication of cell lines used in basic and translational research and complements the STR profiling service.

North America to Dominate the Mycoplasma Testing Market

North America currently dominates the Mycoplasma Testing Market and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of the chronic diseases in the region. Other factors attributing to the growth of this region are the presence of global biotech companies and pharmaceutical players and higher investment into R&D activities in the region. The United States holds the majority of the market in the North America region; this is due to the rising healthcare expenditure, along with the rapid adoption of point-of-care testing.

Competitive Landscape

Companies are focusing on various growth strategies such as new product launches, collaborations, acquisitions, partnerships to enhance their market presence. The major players include Abbott, Agilent Technologies, Charles River Laboratories International, Inc., Eurofins Scientific, F. Hoffmann-La Roche Ltd, Lonza Group, Merck KGaA, PromoCell GmbH, Sartorius AG, and Thermo Fisher Scientific, Inc., among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increased Governmental Initiatives and Funding in Research Activities
    • 4.2.2 Increasing Demand for Fast, Accurate, and Affordable Testing
    • 4.2.3 Increasing Cell Culture Contamination
  • 4.3 Market Restraints
    • 4.3.1 Stringent Government Regulations
    • 4.3.2 High Degree of Consolidation for New Entrants
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product
    • 5.1.1 Instruments
    • 5.1.2 Kits and Reagents
  • 5.2 Technology
    • 5.2.1 PCR
    • 5.2.2 ELISA
    • 5.2.3 Direct Assay
    • 5.2.4 Indirect Assay
    • 5.2.5 Enzymatic Methods
    • 5.2.6 DNA Staining
    • 5.2.7 Others
  • 5.3 Application
    • 5.3.1 Cell Line Testing
    • 5.3.2 Virus Testing
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 ATCC
    • 6.1.3 Bionique Testing Laboratories, Inc.
    • 6.1.4 Charles River Laboratories International, Inc.
    • 6.1.5 Eurofins Scientific
    • 6.1.6 Lonza Group Ltd.
    • 6.1.7 Merck KGaA
    • 6.1.8 Bionique Testing Laboratories, Inc.
    • 6.1.9 PromoCell GmbH
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top